<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035174</url>
  </required_header>
  <id_info>
    <org_study_id>C18-56</org_study_id>
    <nct_id>NCT04035174</nct_id>
  </id_info>
  <brief_title>Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa</brief_title>
  <acronym>EOLoa</acronym>
  <official_title>Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the diagnosis performances of the LTS-2 DEC patch for
      onchocerciasis compared to the gold standard which are the skin snips. This study will be
      conducted in Cameroon in two different areas : Ngog-Mapubi and Bafia Health Districts (one
      area only endemic for onchocerciasis, and one area endemic for both loiasis and
      onchocerciasis).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each participant will have both a LTS-2 patch applied on the skin and a skin snip performed.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Results from LTS-2 patch will be immediately known by both participant and investigators ; but results from skin snips will be masked both for participant and investigators.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of the patch</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of individuals having developed a generalized Mazzotti's reaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of the patch</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of individuals for whom the patches are spontaneously removed from the skin during the 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis performances</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of the sensibility, specificity, and predictive values of the LTS-2 DEC patch compared to the results from the skin snips.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loiasis and cross-reactivity assessment</measure>
    <time_frame>24 hours</time_frame>
    <description>Loiasis impact of the diagnosis performances of the LTS-2 DEC patch. Loiasis will be assessed with thick blood smears and a microscopic examination ; and with PCR in the skin snips</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Semi-quantitative scoring of the LTS-2 DEC patch results</measure>
    <time_frame>24 hours</time_frame>
    <description>Relationship between the number of microfilariae of O. volvulus and the skin reaction under the patch (0 no reaction, 1: &lt; 50% of the skin under the patch, 2: &gt;50% of the skin under the patch, and 3: reaction under all the skin surface of the patch)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Onchocerciasis</condition>
  <condition>Loiasis</condition>
  <condition>Diagnoses Disease</condition>
  <condition>Neglected Diseases</condition>
  <arm_group>
    <arm_group_label>LTS-2 DEC patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a transdermal device with diethylcarbamazine (DEC) applied directly on the skin. The reading will be done 24 hours after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Skin snip</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A skin snip will be performed using a 2 mm Holth corneoscleral's punch. Once done, the microfilariae of Onchocerca volvulus will be counted with a microscope.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LTS-2 DEC patch</intervention_name>
    <description>After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (&lt; 50% skin surface under the patch), medium reaction (&gt; 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).</description>
    <arm_group_label>LTS-2 DEC patch</arm_group_label>
    <arm_group_label>Skin snip</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin snips</intervention_name>
    <description>Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.</description>
    <arm_group_label>LTS-2 DEC patch</arm_group_label>
    <arm_group_label>Skin snip</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All voluntary adults

        Exclusion Criteria:

          -  General acute infection (temperature ≥ 38,5°C)

          -  Impaired general condition

          -  Ivermectin taken in the 6 last months

          -  Known allergies to one of the component of the patch

          -  Dermatological acute infection (bacterial, atopic, prurigo, or zona)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cédric B Chesnais, MD</last_name>
    <phone>+33467416162</phone>
    <email>cedric.chesnais@ird.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Recherche sur les filarioses et autres maladies tropicales (CRFilMT)</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlotte Bizet, PharmD</last_name>
      <email>charlotte.bizet@ird.fr</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Kamgno, MD</last_name>
      <phone>237222202442</phone>
      <email>kamgno@crfilmt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Kamgno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Health Public</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Neglected Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

